BR112016024214B8 - Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal - Google Patents
Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonalInfo
- Publication number
- BR112016024214B8 BR112016024214B8 BR112016024214A BR112016024214A BR112016024214B8 BR 112016024214 B8 BR112016024214 B8 BR 112016024214B8 BR 112016024214 A BR112016024214 A BR 112016024214A BR 112016024214 A BR112016024214 A BR 112016024214A BR 112016024214 B8 BR112016024214 B8 BR 112016024214B8
- Authority
- BR
- Brazil
- Prior art keywords
- monoclonal antibody
- mabs
- fragments
- pharmaceutical composition
- partially humanized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461981240P | 2014-04-18 | 2014-04-18 | |
| US61/981,240 | 2014-04-18 | ||
| PCT/US2015/026595 WO2015161311A2 (en) | 2014-04-18 | 2015-04-20 | Humanized anti-tf-antigen antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112016024214A2 BR112016024214A2 (pt) | 2018-01-23 |
| BR112016024214B1 BR112016024214B1 (pt) | 2023-11-14 |
| BR112016024214B8 true BR112016024214B8 (pt) | 2023-12-26 |
Family
ID=54324717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016024214A BR112016024214B8 (pt) | 2014-04-18 | 2015-04-20 | Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11130821B2 (https=) |
| EP (2) | EP3797793A1 (https=) |
| JP (1) | JP6740135B2 (https=) |
| KR (1) | KR102413809B1 (https=) |
| CN (1) | CN106488774B (https=) |
| AU (1) | AU2015247358B2 (https=) |
| BR (1) | BR112016024214B8 (https=) |
| ES (1) | ES2843546T3 (https=) |
| MX (2) | MX378944B (https=) |
| RU (1) | RU2699717C2 (https=) |
| WO (1) | WO2015161311A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118267470A (zh) * | 2017-04-13 | 2024-07-02 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| JP2020534332A (ja) * | 2017-09-22 | 2020-11-26 | イミュノジェン， インコーポレイテッド | カチオン交換クロマトグラフィーを使用した三重軽鎖抗体の分離 |
| CA3094827A1 (en) * | 2018-03-28 | 2019-10-03 | Mitsubishi Tanabe Pharma Corporation | Drug conjugates of cmet monoclonal binding agents, and uses thereof |
| KR102523019B1 (ko) | 2018-05-30 | 2023-04-18 | 내셔날 헬스 리서치 인스티튜트 | 항-a베타 항체 및 이의 용도 |
| CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| EP4257199A3 (en) | 2018-12-21 | 2024-01-10 | Ose Immunotherapeutics | Humanized anti-human-pd-1 antibody |
| BR112021012027A2 (pt) | 2018-12-21 | 2021-11-03 | Ose Immunotherapeutics | Molécula bifuncional direcionada contra pd-1 humano |
| AU2019409805A1 (en) | 2018-12-21 | 2021-07-22 | Ose Immunotherapeutics | Bifunctional anti-PD-1/SIRPA molecule |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| US20230119066A1 (en) * | 2020-03-23 | 2023-04-20 | Bristol-Myers Squibb Company | Anti-ccr8 antibodies for treating cancer |
| CN121270708B (zh) * | 2025-12-08 | 2026-03-17 | 宁波大学附属第一医院 | 一种纳米抗体及其在制备cd176阳性肿瘤癌症治疗或诊断药物中的应用 |
| CN121270707B (zh) * | 2025-12-08 | 2026-03-17 | 宁波大学附属第一医院 | 一种特异性结合cd176蛋白的纳米抗体及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050260680A1 (en) * | 2004-04-16 | 2005-11-24 | Vanderbilt University | Methods of diagnosing and treating autoimmune diseases |
| EP1789027B1 (en) * | 2004-07-26 | 2013-09-04 | The Research Foundation Of State University Of New York | Therapeutic use of anti-tf-antigen antibody |
| GB0510790D0 (en) * | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| MX2008012023A (es) | 2006-03-21 | 2008-10-01 | Wyeth Corp | Metodos para prevenir y tratar enfermedades amiloidogenicas. |
| EP2161031A1 (en) * | 2008-09-05 | 2010-03-10 | SuppreMol GmbH | Fc gamma receptor for the treatment of B cell mediated multiple sclerosis |
| IN2012DN03348A (https=) * | 2009-10-16 | 2015-10-23 | Biorealites | |
| EP2347769A1 (en) * | 2010-01-20 | 2011-07-27 | Glycotope GmbH | Cancer stem cell markers and uses thereof |
| EP2407487A1 (en) * | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
| CA2832389A1 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
| JP6124800B2 (ja) * | 2011-11-30 | 2017-05-10 | 中外製薬株式会社 | 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬 |
| CN102796144A (zh) * | 2012-08-22 | 2012-11-28 | 山东大学 | Tf抗原及其类似物、和其化学酶法合成方法及其应用 |
| US10023651B2 (en) * | 2014-04-18 | 2018-07-17 | The Research Foundation For The State University Of New York | Humanized anti-TF-antigen antibodies |
-
2015
- 2015-04-20 BR BR112016024214A patent/BR112016024214B8/pt active IP Right Grant
- 2015-04-20 WO PCT/US2015/026595 patent/WO2015161311A2/en not_active Ceased
- 2015-04-20 ES ES15780559T patent/ES2843546T3/es active Active
- 2015-04-20 EP EP20197413.6A patent/EP3797793A1/en active Pending
- 2015-04-20 JP JP2016558558A patent/JP6740135B2/ja active Active
- 2015-04-20 RU RU2016143552A patent/RU2699717C2/ru active
- 2015-04-20 CN CN201580027114.8A patent/CN106488774B/zh active Active
- 2015-04-20 EP EP15780559.9A patent/EP3131581B1/en active Active
- 2015-04-20 KR KR1020167031646A patent/KR102413809B1/ko active Active
- 2015-04-20 AU AU2015247358A patent/AU2015247358B2/en active Active
- 2015-04-20 MX MX2016013686A patent/MX378944B/es unknown
-
2016
- 2016-10-18 MX MX2021000439A patent/MX2021000439A/es unknown
-
2018
- 2018-05-10 US US15/976,500 patent/US11130821B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6740135B2 (ja) | 2020-08-12 |
| BR112016024214B1 (pt) | 2023-11-14 |
| EP3797793A1 (en) | 2021-03-31 |
| US20180258182A1 (en) | 2018-09-13 |
| MX378944B (es) | 2025-03-10 |
| RU2699717C2 (ru) | 2019-09-09 |
| CN106488774A (zh) | 2017-03-08 |
| BR112016024214A2 (pt) | 2018-01-23 |
| AU2015247358A1 (en) | 2016-11-10 |
| CA2943681A1 (en) | 2015-10-22 |
| MX2016013686A (es) | 2017-03-31 |
| MX2021000439A (es) | 2021-03-25 |
| KR20170010356A (ko) | 2017-01-31 |
| EP3131581A2 (en) | 2017-02-22 |
| ES2843546T3 (es) | 2021-07-19 |
| JP2017518260A (ja) | 2017-07-06 |
| RU2016143552A3 (https=) | 2018-11-14 |
| KR102413809B1 (ko) | 2022-06-28 |
| WO2015161311A3 (en) | 2015-12-10 |
| EP3131581A4 (en) | 2018-02-21 |
| RU2016143552A (ru) | 2018-05-21 |
| AU2015247358B2 (en) | 2020-02-27 |
| WO2015161311A2 (en) | 2015-10-22 |
| US11130821B2 (en) | 2021-09-28 |
| CN106488774B (zh) | 2019-11-01 |
| EP3131581B1 (en) | 2020-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016024214B8 (pt) | Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal | |
| CO2019012210A2 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos | |
| CL2021002008A1 (es) | Proteinas de unión de antígeno del receptor gamma anti-il2. | |
| MX2025000370A (es) | Anticuerpos anti-ctla4 y metodos para elaborarlos y usarlos | |
| MX2019014318A (es) | Proteinas de union a nectina-4 y metodos de uso de las mismas. | |
| BR112018011336A2 (pt) | anticorpo anti-fcrl5 isolado ou um fragmento de ligação ao antígeno do mesmo, anticorpo scfv anti-fcrl5 isolado, anticorpo isolado ou porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico isolado, vetor de expressão, célula hospedeira, método para detectar fcrl5 em uma célula ou tecido inteiro, método para tratar câncer em um indivíduo, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo, kit para tratar câncer | |
| BR112016020752A2 (pt) | ?anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, métodos para tratamento de um câncer ou tumor expressando egfrviii e para tratamento de um câncer, redução de crescimento de tumor e/ou causação de regressão de tumor em um paciente? | |
| BR112017025191A2 (pt) | anticorpos contra ox40 e uso dos mesmos | |
| BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
| PH12016501384B1 (en) | Human antibodies to pd-l1 | |
| MX2012011718A (es) | Anticuerpos anti-erbb3. | |
| HK1255039A1 (zh) | 对pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法 | |
| AR107442A1 (es) | Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer | |
| EA201891084A1 (ru) | Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение | |
| CO7160115A2 (es) | Proteinas de unión a antigeno que se unen a pd-l1 | |
| EP4249065A3 (en) | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors | |
| EA201590671A1 (ru) | Комбинация антител к kir и антител к pd-1 для лечения злокачественной опухоли | |
| EA201490825A1 (ru) | Tdp-43-специфически связывающие молекулы | |
| BR112012028764A2 (pt) | anticor-pos antifgfr2 | |
| MX2015012922A (es) | Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular. | |
| EA201590459A1 (ru) | Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение | |
| BR112015014621A2 (pt) | Anticorpos anti-h7cr | |
| BR112017004510A2 (pt) | anticorpos monoclonais isolados; anticorpos monoclonais ou fragmentos de ligação a antígenos do mesmo; composição; moléculas polinucleotídicas isoladas; polipeptídeo recombinante; polipeptídeos; célula hospedeira; método de fabricação de um anticorpo; uso de um agente para o tratamento de câncer em um paciente; usos de anticorpo monoclonal ou fragmento de ligação a antígenos do mesmo para o tratamento de um sujeito que sofre de um câncer; uso de anticorpo monoclonal para o tratamento de um sujeito que sofre de um câncer; composição compreendendo um anticorpo de ligação a agr2; composição compreendendo um anticorpo de ligação a c4.4a; composição compreendendo um anticorpo de ligação a agr2 e um anticorpo de ligação a c4.4a; composição compreendendo um anticorpo; uso de um anticorpo de ligação a agr2; uso de um anticorpo de ligação a c4.4a; uso de um anticorpo; e kit compreendendo um anticorpo | |
| AR104484A1 (es) | Anticuerpos anti-psma como agentes terapéuticos | |
| MX389103B (es) | Anticuerpos contra ticagrelor y métodos de uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/04/2015, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE A RPI 2758 DE 14/11/2023, QUANTO AO ITEM (73) ENDERECO DO TITULAR. |